Ongoing phase 3 clinical trials are testing the medication for weight management, osteoarthritis, NAFLD, cardiovascular risk reduction, type 2 diabetes, and moderate to severe obstructive sleep apnea in obese and overweight patients
CMS was aiming for a critical mass of Part D sponsors to participate and established a threshold participation rate of 80% for 2027
January 9, 2024 Liviniti, a pharmacy benefit manager (PBM) committed to transparent pricing, announced today that it is partnering with Nooms enterprise unit, Noom for Work, to assist U.S
The full effects, especially the thermogenic and fat-oxidation benefits from glucagon activation, typically do not manifest until you reach the 4 to 8 mg range
Do any of these sound familiar